Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice

Tushar G. Kokate, Melissa K. Banks, Tamika Magee, Shun Ichi Yamaguchi, Michael A Rogawski

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Progesterone is an effective anticonvulsant against pentylenetetrazol (PTZ) seizures. This action is hypothesized to require the metabolic conversion of progesterone to the γ-aminobutyric acid(A) receptor potentiating neuroactive steroid allopregnanolone by 5α-reductase isoenzymes followed by 3α-hydroxy oxidoreduction. We evaluated this possibility using the competitive 5α-reductase inhibitor finasteride. Progesterone (50-200 mg/kg, i.p.) protected mice against PTZ-induced seizures in a dose-dependent manner (ED50, 94 mg/kg). Pretreatment with finasteride (50-300 mg/kg, i.p.) produced a dose-dependent (ED50, 146 mg/kg) reversal of the protective effects of progesterone (2 x ED50 dose = 188 mg/kg). In contrast, finasteride (up to 300 mg/kg) failed to affect the anticonvulsant activity of allopregnanolone (10-30 mg/kg, i.p.; ED50, 12 mg/kg). Finasteride (up to 300 mg/kg) did not block the protective effect of high doses of progesterone (250-350 mg/kg) on tonic hindlimb extension in the maximal electroshock seizure test (progesterone ED50, 235 mg/kg). The anticonvulsant activity of progesterone against PTZ-induced seizures can be blocked by 5α-reductase inhibition, providing strong evidence that the anticonvulsant effect of the steroid in this model is mediated by its active metabolite allopregnanolone.

Original languageEnglish (US)
Pages (from-to)679-684
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume288
Issue number2
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Finasteride
Anticonvulsants
Progesterone
Oxidoreductases
Pregnanolone
Pentylenetetrazole
Seizures
Steroids
Aminobutyrates
Electroshock
Hindlimb
Isoenzymes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. / Kokate, Tushar G.; Banks, Melissa K.; Magee, Tamika; Yamaguchi, Shun Ichi; Rogawski, Michael A.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 288, No. 2, 02.1999, p. 679-684.

Research output: Contribution to journalArticle

Kokate, Tushar G. ; Banks, Melissa K. ; Magee, Tamika ; Yamaguchi, Shun Ichi ; Rogawski, Michael A. / Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. In: Journal of Pharmacology and Experimental Therapeutics. 1999 ; Vol. 288, No. 2. pp. 679-684.
@article{1aa06f4860e34347b9718f5762b79f2c,
title = "Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice",
abstract = "Progesterone is an effective anticonvulsant against pentylenetetrazol (PTZ) seizures. This action is hypothesized to require the metabolic conversion of progesterone to the γ-aminobutyric acid(A) receptor potentiating neuroactive steroid allopregnanolone by 5α-reductase isoenzymes followed by 3α-hydroxy oxidoreduction. We evaluated this possibility using the competitive 5α-reductase inhibitor finasteride. Progesterone (50-200 mg/kg, i.p.) protected mice against PTZ-induced seizures in a dose-dependent manner (ED50, 94 mg/kg). Pretreatment with finasteride (50-300 mg/kg, i.p.) produced a dose-dependent (ED50, 146 mg/kg) reversal of the protective effects of progesterone (2 x ED50 dose = 188 mg/kg). In contrast, finasteride (up to 300 mg/kg) failed to affect the anticonvulsant activity of allopregnanolone (10-30 mg/kg, i.p.; ED50, 12 mg/kg). Finasteride (up to 300 mg/kg) did not block the protective effect of high doses of progesterone (250-350 mg/kg) on tonic hindlimb extension in the maximal electroshock seizure test (progesterone ED50, 235 mg/kg). The anticonvulsant activity of progesterone against PTZ-induced seizures can be blocked by 5α-reductase inhibition, providing strong evidence that the anticonvulsant effect of the steroid in this model is mediated by its active metabolite allopregnanolone.",
author = "Kokate, {Tushar G.} and Banks, {Melissa K.} and Tamika Magee and Yamaguchi, {Shun Ichi} and Rogawski, {Michael A}",
year = "1999",
month = "2",
language = "English (US)",
volume = "288",
pages = "679--684",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice

AU - Kokate, Tushar G.

AU - Banks, Melissa K.

AU - Magee, Tamika

AU - Yamaguchi, Shun Ichi

AU - Rogawski, Michael A

PY - 1999/2

Y1 - 1999/2

N2 - Progesterone is an effective anticonvulsant against pentylenetetrazol (PTZ) seizures. This action is hypothesized to require the metabolic conversion of progesterone to the γ-aminobutyric acid(A) receptor potentiating neuroactive steroid allopregnanolone by 5α-reductase isoenzymes followed by 3α-hydroxy oxidoreduction. We evaluated this possibility using the competitive 5α-reductase inhibitor finasteride. Progesterone (50-200 mg/kg, i.p.) protected mice against PTZ-induced seizures in a dose-dependent manner (ED50, 94 mg/kg). Pretreatment with finasteride (50-300 mg/kg, i.p.) produced a dose-dependent (ED50, 146 mg/kg) reversal of the protective effects of progesterone (2 x ED50 dose = 188 mg/kg). In contrast, finasteride (up to 300 mg/kg) failed to affect the anticonvulsant activity of allopregnanolone (10-30 mg/kg, i.p.; ED50, 12 mg/kg). Finasteride (up to 300 mg/kg) did not block the protective effect of high doses of progesterone (250-350 mg/kg) on tonic hindlimb extension in the maximal electroshock seizure test (progesterone ED50, 235 mg/kg). The anticonvulsant activity of progesterone against PTZ-induced seizures can be blocked by 5α-reductase inhibition, providing strong evidence that the anticonvulsant effect of the steroid in this model is mediated by its active metabolite allopregnanolone.

AB - Progesterone is an effective anticonvulsant against pentylenetetrazol (PTZ) seizures. This action is hypothesized to require the metabolic conversion of progesterone to the γ-aminobutyric acid(A) receptor potentiating neuroactive steroid allopregnanolone by 5α-reductase isoenzymes followed by 3α-hydroxy oxidoreduction. We evaluated this possibility using the competitive 5α-reductase inhibitor finasteride. Progesterone (50-200 mg/kg, i.p.) protected mice against PTZ-induced seizures in a dose-dependent manner (ED50, 94 mg/kg). Pretreatment with finasteride (50-300 mg/kg, i.p.) produced a dose-dependent (ED50, 146 mg/kg) reversal of the protective effects of progesterone (2 x ED50 dose = 188 mg/kg). In contrast, finasteride (up to 300 mg/kg) failed to affect the anticonvulsant activity of allopregnanolone (10-30 mg/kg, i.p.; ED50, 12 mg/kg). Finasteride (up to 300 mg/kg) did not block the protective effect of high doses of progesterone (250-350 mg/kg) on tonic hindlimb extension in the maximal electroshock seizure test (progesterone ED50, 235 mg/kg). The anticonvulsant activity of progesterone against PTZ-induced seizures can be blocked by 5α-reductase inhibition, providing strong evidence that the anticonvulsant effect of the steroid in this model is mediated by its active metabolite allopregnanolone.

UR - http://www.scopus.com/inward/record.url?scp=0032590065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032590065&partnerID=8YFLogxK

M3 - Article

C2 - 9918575

AN - SCOPUS:0032590065

VL - 288

SP - 679

EP - 684

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -